Cargando…

Crizotinib in the treatment of non-small-cell lung carcinoma

Recent studies have demonstrated the benefit of EGFR tyrosine kinase inhibitors in the treatment of advanced non-small-cell lung cancer (NSCLC). The role of activation of the anaplastic lymphoma kinase (ALK) pathway and the presence of the fusion gene EML4-ALK are new molecular targets in studies in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Płużański, Adam, Piórek, Aleksandra, Krzakowski, Maciej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687470/ https://www.ncbi.nlm.nih.gov/pubmed/23788933 http://dx.doi.org/10.5114/wo.2012.32477

Ejemplares similares

Solitary fibrous tumour along with non-small-cell lung cancer and Doege-Potter syndrome
por: Piórek, Aleksandra, et al.
Publicado: (2019)

Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2023)

Do We Need TNM for Tracheal Cancers? Analysis of a Large Retrospective Series of Tracheal Tumors
por: Piórek, Aleksandra, et al.
Publicado: (2022)

A case of adenoid cystic carcinoma of trachea: treatment complications and radiotherapy role
por: Piórek, Aleksandra, et al.
Publicado: (2021)

Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients
por: Pluzanski, Adam, et al.
Publicado: (2020)

Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2023)

Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study
por: Pluzanski, Adam, et al.
Publicado: (2023)

Clinical use of crizotinib for the treatment of non-small cell lung cancer
por: Roberts, Patrick J
Publicado: (2013)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)

Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2020)

Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib
por: Niu, Fei-Yu, et al.
Publicado: (2015)

Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2020)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Role of Crizotinib in previously treated non-small-cell lung cancer
por: Gupta, Sunil Kumar
Publicado: (2014)

Crizotinib-induced immunogenic cell death in non-small cell lung cancer
por: Liu, Peng, et al.
Publicado: (2019)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Leprieur, Etienne Giroux, et al.
Publicado: (2016)

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
por: Mehta, Anurag, et al.
Publicado: (2020)

Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland
por: Kowalski, Dariusz M., et al.
Publicado: (2012)

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Asai, Nobuhiro, et al.
Publicado: (2014)

Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer
por: Liu, Peng, et al.
Publicado: (2019)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
por: Jain, Rohit K, et al.
Publicado: (2017)

From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
por: Pirker, Robert, et al.
Publicado: (2019)

Effective treatment of MET-amplified non-small cell lung cancer patients with crizotinib: a case description
por: Tang, Mingyue, et al.
Publicado: (2023)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2017)

Imaging features of renal complications after crizotinib treatment for non–small-cell lung cancer: a case report
por: Chan, Wan Ying, et al.
Publicado: (2016)

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2019)

Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
por: Guo, Liting, et al.
Publicado: (2015)

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
por: D’Angelo, Alberto, et al.
Publicado: (2020)

Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2021)

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
por: Ou, Sai-Hong Ignatius
Publicado: (2011)

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
por: Nishio, Makoto, et al.
Publicado: (2018)

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer
por: Kang, Jin, et al.
Publicado: (2018)

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
por: Morcos, Peter N., et al.
Publicado: (2018)

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
por: Wei, Jiacong, et al.
Publicado: (2018)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018)

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
por: Ma, Di, et al.
Publicado: (2019)

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ej2ri76jna14er5r0i4h4ods05